Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19746095 | 1.00 | TSHR (0.49) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL20180695 | 1.00 | TSHR (0.49) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL22087975 | 0.91 | TSHR (0.46) | TSHRALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL19746164 | 0.88 | TSHR (0.49) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL12539606 | 0.88 | ALDH1A1 (0.51) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL11116485 | 0.86 | SMN1; SMN2 (0.48) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL22086823 | 0.85 | TSHR (0.46) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL23620881 | 0.85 | L3MBTL1 (0.51) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL20180360 | 0.85 | L3MBTL1 (0.51) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 | |
| SCHEMBL20180712 | 0.85 | L3MBTL1 (0.51) | TSHRALDH1A1SMN1; SMN2HTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541825-B1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | IDENIX PHARMACEUTICALS LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-3303359-B1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | MSD INTERNATIONAL GMBH (CH) | 2023-08-22 | — | — | US | disclosed |
| CN-110099912-B | Antiviral tenofovir aliphatic ester prodrug | 默沙东公司 | 2021-10-15 | — | — | CN | disclosed |
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | MSD INTERNATIONAL GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10766917-B2 | Nucleotides for the treatment of cancer | IDENIX PHARMACEUTICALS LLC (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190192548-A1 | USE OF CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVESFOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | IDENIX PHARMACEUTICALS LLC (US) | 2018-06-07 | — | — | US | disclosed |
| WO-2018091542-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | IDENIX PHARMACEUTICALS LLC (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155385-A1 | NUCLEOTIDES FOR THE TREATMENT OF CANCER | NUDT1, NTPCR, ENTPD5 | TSHR 4425/4885ALDH1A1 1553/4885SMN1; SMN2 1995/4885 |
| US-11730748-B2 | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases | SLC10A1, PNP, PYGL | TSHR 2275/4885ALDH1A1 1448/4885SMN1; SMN2 1914/4885 |
| US-20210205339-A1 | CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES | SLC10A1, PNP, PYGL | TSHR 2275/4885ALDH1A1 1448/4885SMN1; SMN2 1914/4885 |
| US-20190192548-A1 | USE OF CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVESFOR THE TREATMENT OF VIRAL DISEASES | PNP, ENTPD5, TYMP | TSHR 3306/4885ALDH1A1 1921/4885SMN1; SMN2 1230/4885 |
| US-10766917-B2 | Nucleotides for the treatment of cancer | NUDT1, NTPCR, ENTPD5 | TSHR 4425/4885ALDH1A1 1553/4885SMN1; SMN2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.